title: Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.
abstract: The importance of nitric oxide (NO) in vascular physiology is irrefutable; it stimulates the intracellular production of cyclic guanosine monophosphate (cGMP), initiating vascular smooth muscle relaxation. This biochemical process increases the diameter of small arteries, regulating blood flow distribution between arterioles and the microvasculature. The kidney is no exception, since NO predominantly dilates the glomerular afferent arterioles. It is now evident that the vascular production of cGMP can be augmented by inhibitors of phosphodiesterase type 5 (PDE 5), the enzyme which breakdowns this cyclic nucleotide. This has clinical relevance, since diabetic nephropathy (DN) a major microvascular complication of diabetes mellitus and the most common cause of end-stage renal disease, increases intraglomerular capillary pressure, leading to glomerular hypertension. PDE 5 inhibitors may have, therefore, the potential to reduce glomerular hypertension. This review describes the use of PDE 5 inhibitors to improve the metabolic, haemodynamic and inflammatory pathways/responses, all of which are dysfunctional in DN.
authors: Cecil Stanley Thompson, Department of Surgery, Division of Surgery and Interventional Science, University College London Medical School, London, NW3 2QG, United Kingdom.
authors: Cecil Stanley
authors: CS
authors: Thompson
keywords: Angiotensin II; Diabetic nephropathy; Glomerular filtration rate; Inflammation; Phosphodiesterase type 5
references: Am J Nephrol. 2009;29(3):274-82
references: 18812693
references: Kidney Int. 2005 Sep;68(3):1250-7
references: 16105058
references: Adv Chronic Kidney Dis. 2011 Jan;18(1):28-41
references: 21224028
references: Diabet Med. 1991 Jul;8(6):540-2
references: 1653676
references: Diabetes. 1973 Sep;22(9):706-12
references: 4728209
references: J Am Soc Nephrol. 2006 Jun;17(6):1703-9
references: 16672313
references: Kidney Int. 2005 Nov;68(5):2131-42
references: 16221212
references: BMJ. 2000 Dec 9;321(7274):1440-4
references: 11110735
references: Kidney Int. 1999 Jan;55(1):29-62
references: 9893113
references: Annu Rev Biochem. 1994;63:175-95
references: 7526779
references: J Invest Dermatol. 2007 May;127(5):1009-17
references: 17435786
references: J Clin Pathol. 2007 Jan;60(1):18-26
references: 17213346
references: Curr Drug Targets. 2013 Apr;14(4):490-6
references: 23316933
references: J Am Soc Nephrol. 2007 Aug;18(8):2303-10
references: 17599973
references: Front Endocrinol (Lausanne). 2013 Feb 06;4:7
references: 23390421
references: Hypertension. 2001 Apr;37(4):1053-9
references: 11304502
references: Nat Clin Pract Urol. 2005 May;2(5):239-47
references: 16474835
references: Curr Pharm Des. 2006;12(27):3459-65
references: 17017939
references: Diabetes Metab. 2006 Jun;32(3):223-8
references: 16799398
references: MMW Fortschr Med. 2005 May 26;147(21):43-6
references: 15966171
references: Diabetes. 1997 Sep;46 Suppl 2:S104-11
references: 9285510
references: Curr Opin Nephrol Hypertens. 2008 Nov;17(6):600-3
references: 18941353
references: JAMA. 1976 Oct 18;236(16):1861-3
references: 989537
references: Nephrol Dial Transplant. 2005 Nov;20(11):2420-6
references: 16115854
references: Eur J Pharmacol. 2003 Sep 12;477(2):171-8
references: 14519421
references: Ethn Dis. 2005 Summer;15(3):418-23
references: 16108301
references: J Hypertens. 2000 Feb;18(2):179-85
references: 10694186
references: Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):26-36
references: 12524221
references: Am Fam Physician. 2005 Jul 1;72(1):96-9
references: 16035688
references: J Hypertens Suppl. 2006 Mar;24(1):S45-50
references: 16601573
references: Eur J Med Res. 2013 Feb 22;18:4
references: 23432977
references: Cardiol Rev. 2007 Mar-Apr;15(2):76-86
references: 17303994
references: N Engl J Med. 2001 Sep 20;345(12):861-9
references: 11565518
references: Nephrol Dial Transplant. 1997 Jun;12(6):1149-54
references: 9198043
references: Nephrol Dial Transplant. 2001;16 Suppl 1:2-5
references: 11369811
references: Curr Drug Targets. 2007 Aug;8(8):952-9
references: 17691932
references: J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S18-21
references: 15938027
references: BJU Int. 2005 Jul;96(1):164-8
references: 15963142
references: Curr Hypertens Rep. 2006 May;8(2):153-7
references: 16672149
references: N Engl J Med. 1993 Nov 11;329(20):1456-62
references: 8413456
references: Amino Acids. 2006 Jul;31(1):1-9
references: 16733619
references: Biomed Pharmacother. 2010 Jan;64(1):35-43
references: 19766439
references: In Vivo. 2007 Sep-Oct;21(5):851-4
references: 18019423
references: Hypertension. 2006 Oct;48(4):519-26
references: 16952978
references: Diabetol Metab Syndr. 2009 Sep 21;1(1):10
references: 19825147
references: Pharmacotherapy. 2005 Nov;25(11):1602-20
references: 16232022
references: Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):69-84
references: 17318765
references: Eur J Pharmacol. 2001 Aug 3;425(1):57-64
references: 11672575
references: Br J Pharmacol. 2011 Mar;162(6):1389-400
references: 21133896
references: Diabetes. 2000 Mar;49(3):476-84
references: 10868971
references: Scand J Clin Lab Invest. 2006;66(4):299-307
references: 16777758
references: Med J Malaysia. 2005 Jun;60(2):146-50
references: 16114154
references: QJM. 2002 Jan;95(1):41-9
references: 11834772